The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Ultrasensitive circulating tumor DNA (ctDNA) minimal residual disease (MRD) detection in early stage non-small cell lung cancer (NSCLC).
 
James M. Isbell
Employment - OptumHealth (I)
Stock and Other Ownership Interests - LumaCyte
Consulting or Advisory Role - AstraZeneca; Merck
Research Funding - Foresight Diagnostics (Inst)
 
Jordan Scott Goldstein
No Relationships to Disclose
 
Emily G. Hamilton
No Relationships to Disclose
 
Si-Yang Liu
No Relationships to Disclose
 
Jordan Eichholz
No Relationships to Disclose
 
Darren J. Buonocore
No Relationships to Disclose
 
Valerie W. Rusch
Other Relationship - NIH/Coordinating Center for Clinical Trials
(OPTIONAL) Uncompensated Relationships - Cancer Research UK
 
Matthew Bott
Honoraria - Intuitive Surgical
Consulting or Advisory Role - AstraZeneca/Merck; Iovance Biotherapeutics
Research Funding - Celsius Therapeutics (Inst); Obsidian Therapeutics (Inst)
 
Daniela Molena
Honoraria - Bristol-Myers Squibb/Pfizer; Merck
Consulting or Advisory Role - AstraZeneca/MedImmune; Boehringer Ingelheim; Boston Scientific; Johnson & Johnson; medtronic
 
Gaetano Rocco
Consulting or Advisory Role - Scanlan, AstraZeneca, Medtronic
 
Soo-Ryum Yang
No Relationships to Disclose
 
Charles M. Rudin
Consulting or Advisory Role - Abbvie; Amgen; AstraZeneca; Auron Therapeutics; Bridge Medicines; D2G Oncology; Daiichi Sankyo/UCB Japan; DISCO; Earli; Genentech/Roche; Harpoon Therapeutics; Jazz Pharmaceuticals; Kowa; Merck
Research Funding - Daiichi Sankyo (Inst); Merck (Inst); Roche/Genentech (Inst)
 
David R Jones
Consulting or Advisory Role - AstraZeneca; More Health
Speakers' Bureau - DAVA Oncology; Genentech/Roche
Expert Testimony - MGH Hospitals
Travel, Accommodations, Expenses - DAVA Oncology
(OPTIONAL) Uncompensated Relationships - Merck
 
Alanna Roff
Employment - Foresight Diagnostics
Stock and Other Ownership Interests - Foresight Diagnostics
 
Andre Schultz
Employment - Foresight Diagnostics
Stock and Other Ownership Interests - Foresight Diagnostics
 
Jake J. Chabon
Employment - Foresight Diagnostics
Stock and Other Ownership Interests - Foresight Diagnostics
 
David Matthew Kurtz
Stock and Other Ownership Interests - Foresight Diagnostics
Consulting or Advisory Role - Roche, Adaptive Biotechnologies and Genentech
Patents, Royalties, Other Intellectual Property - Foresight Diagnostics
 
Ash A. Alizadeh
Stock and Other Ownership Interests - in CiberMed, FortySeven Inc, and Foresight Diagnostics
Consulting or Advisory Role - Genentech, Roche, Chugai, Gilead, and Celgene
Research Funding - Bristol-Myers Squibb
Patents, Royalties, Other Intellectual Property - patent filings related to cancer biomarkers
 
Bob T. Li
Research Funding - Ambrx (Inst); Amgen (Inst); AstraZeneca (Inst); Bolt Biotherapeutics (Inst); Daiichi Sankyo (Inst); Hengrui Therapeutics (Inst); Lilly (Inst); MORE Health (Inst); Roche/Genentech (Inst)
Patents, Royalties, Other Intellectual Property - Karger Publishers - Book royalty; Shanghai Jiao Tong University Press - Book royalty; US62/514,661 (Inst); US62/685,057 (Inst)
Travel, Accommodations, Expenses - Amgen
(OPTIONAL) Uncompensated Relationships - Amgen; AstraZeneca; Boehringer Ingelheim; Daiichi Sankyo; Lilly
 
Maximilian Diehn
Leadership - Foresight Diagnostics
Stock and Other Ownership Interests - CiberMed; Foresight Diagnostics; Gritstone Bio
Honoraria - Bristol-Myers Squibb Japan
Consulting or Advisory Role - AstraZeneca; Genentech; Gritstone Bio; Illumina; Novartis; Regeneron
Research Funding - AstraZeneca (Inst); Illumina (Inst)
Patents, Royalties, Other Intellectual Property - Patent filings on ctDNA detection assigned to Stanford University (Inst); Patent filings on tumor treatment resistance mechanisms assigned to Stanford University (Inst); Royalties from Foresight Diagnostics for patent licensing fees; Royalties from Roche for patent licensing fees
Travel, Accommodations, Expenses - Foresight Diagnostics; Regeneron